Concurrent use of statins does not influence efficacy of maraviroc in Maraviroc versus Optimized Therapy in Viremic Antiretroviral Treatment-Experienced Patients 1 and 2 trials

Chemokine receptors 5 (CCR.5), the target of maraviroc (MVC), are located on cholesterol-rich domains called 'lipid rafts' within cell membranes. In-vitro data suggest that 3-hydroxy-3-methyl-glutaryl co-reductase inhibitors (statins) may reduce lipid raft numbers, which in turn may alter CCR5 availability for HIV attachment. In-vivo data indicate limited or no independent antiretroviral activity for statins. We hypothesized that statins could alter the activity of MVC by reducing the number of target receptors.